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Summary. Experimental herpesvirus retinopathy 
presents a unique model of a transient inflammatory 
response in the virus-injected eye and subsequent acute 
retinal necrosis and chronic inflammation in the 
contralateral eye. For 6 days after infection, VEGF, 
TGFIJ,, and TGFB2 were associated only with 
inflammatory cells in the injected eye. By 6 days (after 
viral antigens were no longer detected), VEGF and 
TGFB2 were upregulated in retinas of injected eyes until 
8-10 days. In contralateral eyes, VEGF was first 
demonstrated in the retina at 6-7 days (prior to the 
appearance of viral antigens) and TGFD2 at 7-8 days. 
Staining for these factors was also evident around areas 
of necrosis. The VEGF receptor, flt- l ,  was associated 
with ganglion cells and the inner nuclear layer of normal 
and experimental mice and i t  was also demonstrated 
around areas of necrosis. Another VEGF receptor, flk-l, 
was localized to Miiller cell processes and the outer 
plexiform layer in normal and experimental mice. 
Coincident with VEGF upregulation in the retinas of 
herpesvirus-l injected mice, there was increased flk-l in 
ganglion cells and the inner and outer nuclear layers. IL- 
6 was associated with Miiller cell endfeet in normal 
mice. Following unilateral intraocular inoculation, 1L-6 
spread along the Miiller cell processes and some 
astrocytes demonstrated IL-6 in both eyes at 6-8 days. 
The  present study demonstrates  that intraocular 
inoculation of herpesvirus is sufficient to induce VEGF, 
flk-l ,  TGFB2, and IL-6 in the retinas of injected and 
contralateral eyes. Further investigation of common 
signaling pathways for these factors during responses to 
viral infection and the development of acute retinal 
necrosis could provide information useful for therapeutic 
intervention in  human herpesvirus retinopathy. 
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Introduction 
Vascular endothelial growth factor (VEGF) is 
induced by hypoxia (Plate et al., 1992; Shweiki et al., 
1992; Goldberg and Schneider, 1994; Hashimoto et al., 
1994; Minchenko, et al., 1994a,b; Levy et al., 1995; 
Pierce et al., 1995) and its induction is associated with 
angiogenesis in hypoxic tissues (Miller et al., 1994; 
Stone et al., 1995; Murata et al., 1996). In some cases, 
however, VEGF induction occurs in tissues in which 
hypoxia does not appear to be a feature and angiogenesis 
does not occur. Inflammatory ocular disorders that do 
not present with apparent pathological evidence of 
hypoxia include autoimmune disorders,  such as  
experimental  autoimmune uveoretinitis (EAU), 
infections, and aphakic or pseudophakic macular edema 
(Vinores et al., 1997). These findings suggest that factors 
other than hypoxia may be capable of inducing VEGF in 
the retina in pathological conditions, as  has been 
demonstrated in other systems. A number of other 
factors, such as interleukin-16 (Ben-AV et al., 1995; Li et 
al., 1995; Jackson et al., 1997; Ristimaki et al., 1998) 
prostaglandins El  and E2 (Harada et al., 1994), tumor 
necrosis factor-a (Ryuto et al., 1996), epidermal growth 
factor, platelet-derived growth factor-BB, basic 
fibroblast growth factor  (Tsai e t  al., 1995), and 
inflammatory cytokines from activated T-cells 
(Samaniego et al., 1998) have been shown to stimulate 
the production and secretion of VEGF in other systems 
and this is also likely to occur in the eye. In disorders 
that do not involve hypoxia, VEGF may be produced by 
resident cells and thereby contr ibute  to a pro- 
inflammatory cascade via recruitment and activation of 










